ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
71 hedge funds and large institutions have $348M invested in Adaptimmune Therapeutics in 2017 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
6% more funds holding
Funds holding: 67 → 71 (+4)
2.7% less ownership
Funds ownership: 11.96% → 9.26% (-2.7%)
16% less capital invested
Capital invested by funds: $416M → $348M (-$68.1M)
Holders
71
Holding in Top 10
2
Calls
$158K
Puts
$108K
Top Buyers
| 1 | +$5.25M | |
| 2 | +$3.62M | |
| 3 | +$2.21M | |
| 4 |
GAMA
Graticule Asia Macro Advisors
New York
|
+$1.69M |
| 5 |
Millennium Management
New York
|
+$1.44M |
Top Sellers
| 1 | -$3.35M | |
| 2 | -$2.67M | |
| 3 | -$2.25M | |
| 4 |
Renaissance Technologies
New York
|
-$1.08M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
-$819K |